Antimicrobial activity of omiganan pentahydrochloride against contemporary fungal pathogens responsible for catheter-associated infections

Antimicrobial Agents and Chemotherapy
Thomas R FritscheRonald N Jones

Abstract

Omiganan, a bactericidal and fungicidal cationic peptide being developed as a topical gel for prevention of catheter-associated infections, inhibited commonly occurring fungal pathogens including Candida spp. (106 isolates) at <or=256 microg/ml and molds (including 10 Aspergillus isolates) at <or=1,024 microg/ml. All fungi were inhibited by omiganan at concentrations well below the 1% (10,000 microg/ml) clinical formulation, including species with reduced susceptibility to azoles and echinocandins.

References

May 25, 1994·JAMA : the Journal of the American Medical Association·D PittetR P Wenzel
Mar 9, 2004·Journal of Clinical Microbiology·Tamara R AndereggUNKNOWN Quality Control Working Group
Sep 10, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E BouzaUNKNOWN Cooperative Group of the European Study Group on Nosocomial Infections (ESGNI)
Sep 10, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·P MuñozUNKNOWN Co-Operative Group of the European Study Group on Nosocomial Infections (ESGNI)
Dec 2, 2004·American Journal of Infection Control·UNKNOWN National Nosocomial Infections Surveillance System
Apr 9, 2005·Journal of Clinical Microbiology·Benito AlmiranteUNKNOWN Barcelona Candidemia Project Study Group
Jul 16, 2005·Current Eye Research·Y Jerold GordonAlison M McDermott
Oct 11, 2005·Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition·Debra S KovacevichUNKNOWN Centers for Disease Control and Prevention
Nov 30, 2006·Journal of Chemotherapy·P Viale, S Stefani
Mar 27, 2007·Biochimica Et Biophysica Acta·Manuel Nuno Melo, Miguel A R B Castanho
Jul 25, 2007·The Journal of Antimicrobial Chemotherapy·Darius Armstrong-James

❮ Previous
Next ❯

Citations

Mar 8, 2013·Future Medicinal Chemistry·Derry K Mercer, Deborah A O'Neil
Jan 15, 2013·International Journal of Antimicrobial Agents·Bing Zhai, Xiaorong Lin
Sep 6, 2011·European Journal of Medicinal Chemistry·Bhuwan B Mishra, Vinod K Tiwari
Jun 16, 2009·International Journal of Antimicrobial Agents·Evelina RubinchikH David Friedland
Jan 21, 2017·Journal of Peptide Science : an Official Publication of the European Peptide Society·Siew Mei Samantha NgCheng San Brian Chia
Feb 2, 2018·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Alicia BotoConcepción C González
Aug 4, 2018·Expert Review of Clinical Pharmacology·Maddalena NapolitanoCataldo Patruno
Dec 12, 2018·Protein and Peptide Letters·María Verónica HúmpolaGeorgina Guadalupe Tonarelli
Feb 12, 2020·Clinical and Translational Science·Tessa Niemeyer-van der KolkMatthijs Moerland
Oct 2, 2016·Journal of Fungi·Kaila M Pianalto, J Andrew Alspaugh
May 28, 2019·The Journal of Antimicrobial Chemotherapy·Sandra N PintoAna Salomé Veiga
Oct 20, 2020·Frontiers in Immunology·Derry K Mercer, Deborah A O'Neil
Mar 4, 2021·Probiotics and Antimicrobial Proteins·Paulina CzechowiczWojciech Kamysz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.